COMPARATIVE ANALYSES OF NILOTINIB VS HIGH-DOSE IMATIB VS SUSTAINING STANDARD-DOSE IMATINIB IN PATIENTS WITH CP CHRONIC MYELOID LEUKEMIA FOLLOWING SUBOPTIMAL MOLECULAR RESPONSE TO FIRST-LINE IMATINIB
HAEMATOLOGICA(2017)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要